FDA approves Merck KGaA’s Pimjetmi for tenosynovial giant cell tumor, Parexel’s Stacy Hurt on when patient input should enter ...
FDA approves Bayer’s asundexian (Sunharbo), the first Factor XIa inhibitor, for secondary stroke prevention. FDA has granted ...
Zoe Lazarre, Claudia Ciciliano, and Shankar Narayanan assess where artificial intelligence (AI) is already proving its value ...
Experts consider what happens when artificial intelligence (A) tools multiply faster than organizations can connect them.
FDA approves Bayer’s asundexian as the first Factor XIa inhibitor for secondary stroke prevention, the FDA requires a new ...
A group of experts explore the advantages of purpose-built artificial intelligence (AI) for healthcare over generic models.
AI can make clinical trials smarter and faster, but lived patient experience remains irreplaceable in guiding research toward ...
AstraZeneca has entered a deal to acquire Omniose, following a three-year exclusive research collaboration between the two organizations that both sides described as productive. C ...
Unnatural Products, adding a macrocyclic peptide discovery platform to complement its antibody engineering. argenx signed a ...
Ignite Proteomics measures phosphorylation states to show which proteins are actively driving a tumor—guiding therapy beyond ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results